Oropharyngeal Dysphagia clinical trials at UCSF
1 research study open to eligible people
Showing trials for
Autologous Muscle Derived Cells for Treatment of Tongue Dysphagia
open to eligible people ages 18 years and up
The primary objective of this double-blind, randomized, placebo-controlled, multicenter clinical trial is to evaluate the safety of AMDC-GIR during the 24 months following 2 consecutive treatments of tongue dysphagia in male and female patients who have undergone surgery and/or chemo- and/or radiotherapy for squamous cell cancer of the oropharynx.
San Francisco, California and other locations
Our lead scientists for Oropharyngeal Dysphagia research studies include Clark Rosen, MD.